Prokip Gordiichuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prokip Gordiichuk has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Mykola Gordiichuk
Shupyk National Healthcare University of Ukraine
5 shared publications - Anastasiia Samusieva
Department of Oncology, Shupyk National Healthcare University of Ukraine
2 shared publications Mykola Gordiichuk
Shupyk National University of Healthcare of Ukraine
2 shared publications- Pavlo Oleksandrovych Korol
Національний університет охорони здоров’я України імені П.Л. Шупика Міністерства охорони здоров’я України, Київ, Україна
2 shared publications - Valerii Zakharychev
Shupyk National University of Health of Ukraine, Kyiv, Ukraine
2 shared publications П.і. Гордійчук
Shupyk National Healthcare University of Ukraine of the Ministry of Health of Ukraine, Kyiv, Ukraine; Municipal Non-Profit Enterprise «Kyiv City Clinical Oncology Center»of the Kyiv City Council, Kyiv, Ukraine
2 shared publications
Latest Publications
- Open Access
- 29 December 2025
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 33 (4) , 484-497
The impact of the tumor microenvironment on the selection of systemic therapy regimens in patients with stage IVa–b gastric cancer based on molecular genetic characteristics
Background. Gastric cancer is more frequently diagnosed at an advanced stage; in Ukraine, nearly 60% of patients have stage III or IV disease at the time of diagnosis, when surgical treatment is either inappropriate or not feasible. Conventional chemotherapy provides only limited improvement in survival; therefore, interest in targeted therapy and immunotherapy as promising treatment modalities is increasing. Purpose – was to present the results of histological, immunohistochemical, and molecular genetic characteristics of gastric cancer and the tumor microenvironment as predictors of prognosis and selection of systemic medical treatment. Materials and Methods. Data retrieval for the review was conducted in accordance with the PRISMA-ScR guidelines. A systematic search was performed in PubMed, Scopus, Google Scholar, and Embase (from 2017 to the present) and was supplemented by a review of major clinical guidelines (NCCN, ESMO) published over the past five years. Results. The results of the literature search over the past ten years demonstrated that an integrated assessment of histological and immunohistochemical characteristics enables more accurate classification of gastric cancer, prediction of its biological aggressiveness, and selection of individualized therapeutic approaches. Moreover, morphological analysis of the tumor – stroma ratio at the invasive front allows for a more precise interpretation of the clinical significance of the tumor microenvironment (TME) and facilitates the identification of novel prognostic markers associated with gastric cancer progression. Molecular genetic characteristics of the tumor (HER2 status, PD-L1 expression [CPS], MSI/MMR status, EBV positivity, and CLDN18.2 expression) determine the feasibility of personalized therapy. In metastatic gastric cancer, the integration of molecular profiling with TME characteristics enables a rational choice among anti-HER2 strategies, antiangiogenic therapy, immunotherapy, or their combinations. Conclusions. Comprehensive characterization of the tumor microenvironment, along with the immunohistochemical and molecular genetic landscape of the tumor stage IVa,b gastric cancer, should become a standard of clinical practice to enable personalized systemic therapy and improve survival outcomes.
- 29 December 2025
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 33 (4) , 484-497
Open AccessThe impact of the tumor microenvironment on the selection of systemic therapy regimens in patients with stage IVa–b gastric cancer based on molecular genetic characteristics
Background. Gastric cancer is more frequently diagnosed at an advanced stage; in Ukraine, nearly 60% of patients have stage III or IV disease at the time of diagnosis, when surgical treatment is either inappropriate or not feasible. Conventional chemotherapy provides only limited improvement in survival; therefore, interest in targeted therapy and immunotherapy as promising treatment modalities is increasing. Purpose – was to present the results of histological, immunohistochemical, and molecular genetic characteristics of gastric cancer and the tumor microenvironment as predictors of prognosis and selection of systemic medical treatment. Materials and Methods. Data retrieval for the review was conducted in accordance with the PRISMA-ScR guidelines. A systematic search was performed in PubMed, Scopus, Google Scholar, and Embase (from 2017 to the present) and was supplemented by a review of major clinical guidelines (NCCN, ESMO) published over the past five years. Results. The results of the literature search over the past ten years demonstrated that an integrated assessment of histological and immunohistochemical characteristics enables more accurate classification of gastric cancer, prediction of its biological aggressiveness, and selection of individualized therapeutic approaches. Moreover, morphological analysis of the tumor – stroma ratio at the invasive front allows for a more precise interpretation of the clinical significance of the tumor microenvironment (TME) and facilitates the identification of novel prognostic markers associated with gastric cancer progression. Molecular genetic characteristics of the tumor (HER2 status, PD-L1 expression [CPS], MSI/MMR status, EBV positivity, and CLDN18.2 expression) determine the feasibility of personalized therapy. In metastatic gastric cancer, the integration of molecular profiling with TME characteristics enables a rational choice among anti-HER2 strategies, antiangiogenic therapy, immunotherapy, or their combinations. Conclusions. Comprehensive characterization of the tumor microenvironment, along with the immunohistochemical and molecular genetic landscape of the tumor stage IVa,b gastric cancer, should become a standard of clinical practice to enable personalized systemic therapy and improve survival outcomes.
- Open Access
- 30 June 2025
- Published by Kharkiv National Medical University in Experimental and Clinical Medicine
- Vol. 94 (2) , 140
Breast cancer in Ukraine: clinics and diagnostics. Current status and prospects of diagnostics (lecture)
The lecture discusses the current state of early Breast Cancer (BC) diagnosis in Ukraine, outlining its epidemiological features, morphological heterogeneity, clinical manifestations, and modern diagnostic methods. BC remains the most common oncological disease among women worldwide, including Ukraine. Each year, over 12,000 new cases are registered in the country, with many patients seeking medical help at advanced stages, which decreases treatment effectiveness and survival rates. The lecture stresses the importance of early diagnosis, achievable through increased physician awareness and widespread screening programs. It summarizes current knowledge on the clinicopathological subtypes of BC, assessment of hormonal receptor status, and the role of immunohistochemical and molecular-genetic testing in treatment decisions. Diagnostic imaging techniques (mammography, tomosynthesis, ultrasound, magnetic resonance imaging) and their diagnostic value are discussed, along with clinical examination algorithms. Special emphasis is placed on modern technologies, especially artificial intelligence, in automated image analysis for mammography and ultrasound. The integration of deep learning with medical imaging data improves diagnostic accuracy, allows detection of pathological changes at the preclinical stage, and reduces diagnostic errors. A key focus is the multidisciplinary approach to managing BC patients, which involves coordination among healthcare providers, adherence to current clinical protocols, and the use of genomic assays (such as Oncotype DX, MammaPrint), with personalized treatment plans. The lecture underlines the necessity of ongoing professional development for healthcare workers at all levels through postgraduate education, aiming to establish standardized algorithms for early BC detection. Overall, the lecture aims to provide students with a thorough understanding of modern principles in breast cancer diagnostics and strategies for enhancing their effectiveness in Ukraine, considering global trends, national challenges, and innovative approaches. Keywords: breast cancer symptoms, diagnostic algorithm, artificial intelligence in diagnosis.
- 30 June 2025
- Published by Kharkiv National Medical University in Experimental and Clinical Medicine
- Vol. 94 (2) , 140
Open AccessBreast cancer in Ukraine: clinics and diagnostics. Current status and prospects of diagnostics (lecture)
The lecture discusses the current state of early Breast Cancer (BC) diagnosis in Ukraine, outlining its epidemiological features, morphological heterogeneity, clinical manifestations, and modern diagnostic methods. BC remains the most common oncological disease among women worldwide, including Ukraine. Each year, over 12,000 new cases are registered in the country, with many patients seeking medical help at advanced stages, which decreases treatment effectiveness and survival rates. The lecture stresses the importance of early diagnosis, achievable through increased physician awareness and widespread screening programs. It summarizes current knowledge on the clinicopathological subtypes of BC, assessment of hormonal receptor status, and the role of immunohistochemical and molecular-genetic testing in treatment decisions. Diagnostic imaging techniques (mammography, tomosynthesis, ultrasound, magnetic resonance imaging) and their diagnostic value are discussed, along with clinical examination algorithms. Special emphasis is placed on modern technologies, especially artificial intelligence, in automated image analysis for mammography and ultrasound. The integration of deep learning with medical imaging data improves diagnostic accuracy, allows detection of pathological changes at the preclinical stage, and reduces diagnostic errors. A key focus is the multidisciplinary approach to managing BC patients, which involves coordination among healthcare providers, adherence to current clinical protocols, and the use of genomic assays (such as Oncotype DX, MammaPrint), with personalized treatment plans. The lecture underlines the necessity of ongoing professional development for healthcare workers at all levels through postgraduate education, aiming to establish standardized algorithms for early BC detection. Overall, the lecture aims to provide students with a thorough understanding of modern principles in breast cancer diagnostics and strategies for enhancing their effectiveness in Ukraine, considering global trends, national challenges, and innovative approaches. Keywords: breast cancer symptoms, diagnostic algorithm, artificial intelligence in diagnosis.
- Open Access
- 23 May 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 3,p. 36-43
Modern recommendations for the medical treatment of epithelial ovarian tumors
Nowadays, ovarian cancer remains the leading cause of death from cancer in women worldwide. In most cases, this disease is diagnosed at a late stage, it is difficult to treat, and it often recurs and progresses rapidly with a poor prognosis for overall survival. The success of ovarian cancer treatment depends on the radicality of surgical intervention and drug treatment, but the last one is characterized by high toxicity. The standard component of drug therapy is platinum-based chemotherapy. If a positive result is achieved after 4–6 courses of chemotherapy, it is justified to prescribe special therapy in a maintenance regimen depending on the presence/absence of BRCA1/BRCA2 mutations and HRD status of the tumor. However, despite of modern achievements in medicine over the past decades, the overall survival rate has not increased significantly.Ovarian cancer is a disease which is characterized by frequent recurrence and progressions. And the prognosis of the disease is better the later the progression occurs. The issue of selecting drug therapy in case of recurrence/progression of the disease remains quite difficult, since there are no clear recommendations for the use of chemotherapy regimens. Also, the reliable predictors of sensitivity to chemotherapy drugs are absent, there is only a 6-month interval for treatment with platinum drugs, which is also inaccurate. Clinical studies have confirmed the sensitivity of ovarian tumors to platinum and PARP inhibitors in the presence of mutations in the BRCA1/BRCA2 genes and other homologous recombination genes. In BRCA1/BRCA2 negative tumors, sensitivity to chemotherapeutic drugs, including platinum-containing drugs, remains insufficiently studied. Therefore, an important task is to find new predictors of sensitivity to platinum drugs that will help to choose the most personalized treatment and avoid unnecessary toxicity.
- 23 May 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 3,p. 36-43
Open AccessModern recommendations for the medical treatment of epithelial ovarian tumors
Nowadays, ovarian cancer remains the leading cause of death from cancer in women worldwide. In most cases, this disease is diagnosed at a late stage, it is difficult to treat, and it often recurs and progresses rapidly with a poor prognosis for overall survival. The success of ovarian cancer treatment depends on the radicality of surgical intervention and drug treatment, but the last one is characterized by high toxicity. The standard component of drug therapy is platinum-based chemotherapy. If a positive result is achieved after 4–6 courses of chemotherapy, it is justified to prescribe special therapy in a maintenance regimen depending on the presence/absence of BRCA1/BRCA2 mutations and HRD status of the tumor. However, despite of modern achievements in medicine over the past decades, the overall survival rate has not increased significantly.Ovarian cancer is a disease which is characterized by frequent recurrence and progressions. And the prognosis of the disease is better the later the progression occurs. The issue of selecting drug therapy in case of recurrence/progression of the disease remains quite difficult, since there are no clear recommendations for the use of chemotherapy regimens. Also, the reliable predictors of sensitivity to chemotherapy drugs are absent, there is only a 6-month interval for treatment with platinum drugs, which is also inaccurate. Clinical studies have confirmed the sensitivity of ovarian tumors to platinum and PARP inhibitors in the presence of mutations in the BRCA1/BRCA2 genes and other homologous recombination genes. In BRCA1/BRCA2 negative tumors, sensitivity to chemotherapeutic drugs, including platinum-containing drugs, remains insufficiently studied. Therefore, an important task is to find new predictors of sensitivity to platinum drugs that will help to choose the most personalized treatment and avoid unnecessary toxicity.
- Open Access
- 31 May 2024
- Published by Professional Event, LLC in Family medicine. European practices
- No. 2,p. 7-12
Organization of Palliative Care Provision in the Palliative Care Department During War Time
The city of Kyiv is characterized by a high level (258.6 cases per 100,000 population) of cancer incidence and mortality. The objective: to determine the problem and prospects of providing inpatient oncology care based on the experience of the department of the Kyiv City Clinical Oncology Center (KCCOC). Materials and methods. A retrospective analysis of the work of the palliative care department of communal non-commercial enterprise “KCCOC” for 2001–2023 was carried out. The center includes a 25-bed hospital and mobile palliative care teams. A multidisciplinary approach was the basis of providing palliative care to an incurable cancer patient. Results. During this period 9,164 cancer patients in the terminal stage with high mortality rate (81.04%) received inpatient care. The average duration of stay in the hospital was 17.7 bed-days. Approximately 6% of patients readmit to the department, some of them – 3-4 times. Approximately 94% of hospitalized patients had a pain syndrome, 86% of patients received opioid analgesia. During this period, mobile palliative care teams registered and served 3,124 cancer patients, among whom 62% of patients were transferred after inpatient treatment, more than 5,700 primary visits were made. The clinical route of the palliative patient was developed and improved, which made it possible to optimize palliative care for a seriously ill oncological patient. The peculiarities of providing palliative care to incurable oncological patients in the conditions of martial law have been determined. Conclusions. Comprehensive palliative care should be a unified system of mobile and stationary care, which will make possible to control the somatic condition of the palliative patient, correct the symptoms of the disease, provide long-term support to the patient at home, which is economically feasible, allows to provide care to a larger number of patients and hospitalize in time if it is necessary. The creation of an extensive system of mobile palliative care is promising in improvement of palliative care for oncology patients (it will reduce the burden on general somatic hospitals and inpatient palliative departments), as well as qualitatively improve the provision of palliative care to patients in the primary care network.
- 31 May 2024
- Published by Professional Event, LLC in Family medicine. European practices
- No. 2,p. 7-12
Open AccessOrganization of Palliative Care Provision in the Palliative Care Department During War Time
The city of Kyiv is characterized by a high level (258.6 cases per 100,000 population) of cancer incidence and mortality. The objective: to determine the problem and prospects of providing inpatient oncology care based on the experience of the department of the Kyiv City Clinical Oncology Center (KCCOC). Materials and methods. A retrospective analysis of the work of the palliative care department of communal non-commercial enterprise “KCCOC” for 2001–2023 was carried out. The center includes a 25-bed hospital and mobile palliative care teams. A multidisciplinary approach was the basis of providing palliative care to an incurable cancer patient. Results. During this period 9,164 cancer patients in the terminal stage with high mortality rate (81.04%) received inpatient care. The average duration of stay in the hospital was 17.7 bed-days. Approximately 6% of patients readmit to the department, some of them – 3-4 times. Approximately 94% of hospitalized patients had a pain syndrome, 86% of patients received opioid analgesia. During this period, mobile palliative care teams registered and served 3,124 cancer patients, among whom 62% of patients were transferred after inpatient treatment, more than 5,700 primary visits were made. The clinical route of the palliative patient was developed and improved, which made it possible to optimize palliative care for a seriously ill oncological patient. The peculiarities of providing palliative care to incurable oncological patients in the conditions of martial law have been determined. Conclusions. Comprehensive palliative care should be a unified system of mobile and stationary care, which will make possible to control the somatic condition of the palliative patient, correct the symptoms of the disease, provide long-term support to the patient at home, which is economically feasible, allows to provide care to a larger number of patients and hospitalize in time if it is necessary. The creation of an extensive system of mobile palliative care is promising in improvement of palliative care for oncology patients (it will reduce the burden on general somatic hospitals and inpatient palliative departments), as well as qualitatively improve the provision of palliative care to patients in the primary care network.
- Open Access
- 3 July 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Oncology
- Vol. 8 (3) , 21-26
Outcomes of the distal rectal cancer treatment depending on the type of sphincter-sparing surgery
Introduction: The increase in mid-ampullary and lower ampullary rectal cancer with disappointing treatment results requires ongoing discussion, research, and improvement of the complex treatment. Materials and methods: We analyzed the results of complex treatment in 442 patients with stages II–III mid-ampullary and lower ampullary rectal cancer that underwent three types of sphincter-sparing surgeries, including low anterior resection (LAR), intersphincteric resection (ISR), and abdomino-anal resection of the rectum (AAR) at the second stage of complex treatment. Results: There was a significant difference between groups in terms of surgery type selection based on the distance from the tumor to the dentate line. When the tumor was located at a distance of 30 mm or less from the dentate line, LAR was performed in 16.4% of cases, whereas ISR and AAR were used in 96.58 and 58.09% of cases, respectively, which is statistically significant (PP0.05), but had a direct correlation with the recurrence-free survival curves. Relapse-free and overall (3 years and 5 years) survival depending on the type of sphincter-preserving surgery did not have a significant difference according to the log-rank test. Conclusion: The more types of surgical intervention surgeons have at their disposal, the more rational it is to select the one that will ensure the best treatment results.
- 3 July 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Oncology
- Vol. 8 (3) , 21-26
Open AccessOutcomes of the distal rectal cancer treatment depending on the type of sphincter-sparing surgery
Introduction: The increase in mid-ampullary and lower ampullary rectal cancer with disappointing treatment results requires ongoing discussion, research, and improvement of the complex treatment. Materials and methods: We analyzed the results of complex treatment in 442 patients with stages II–III mid-ampullary and lower ampullary rectal cancer that underwent three types of sphincter-sparing surgeries, including low anterior resection (LAR), intersphincteric resection (ISR), and abdomino-anal resection of the rectum (AAR) at the second stage of complex treatment. Results: There was a significant difference between groups in terms of surgery type selection based on the distance from the tumor to the dentate line. When the tumor was located at a distance of 30 mm or less from the dentate line, LAR was performed in 16.4% of cases, whereas ISR and AAR were used in 96.58 and 58.09% of cases, respectively, which is statistically significant (PP0.05), but had a direct correlation with the recurrence-free survival curves. Relapse-free and overall (3 years and 5 years) survival depending on the type of sphincter-preserving surgery did not have a significant difference according to the log-rank test. Conclusion: The more types of surgical intervention surgeons have at their disposal, the more rational it is to select the one that will ensure the best treatment results.
- Open Access
- 28 June 2023
- Published by John Paul II University in Biała Podlaska in Health Problems of Civilization
- Vol. 17 (2) , 114-121
EFFICIENCY OF NEOADJUVANT THERAPY OF MALIGNANT TUMORS OF THE MEDIASTINAL AND CHEST WALL
Background: Primary tumors of the mediastinum and chest wall are heterogeneous in morphological structure, united only by anatomical localization. Considering their proximity to the vital structures of the mediastinum, their treatment is a complex task that requires a personalized approach in the selection of neoadjuvant therapy. Material and methods: The results of surgical, combined and complex treatment of 1,375 patients with primary malignant tumors of the mediastinum, and 98 patients with malignant tumors of the chest wall were analyzed. Various treatment methods were used in the neoadjuvant regime: radiotherapy, thermoradiotherapy, chemoradiotherapy and intra-arterial regional chemotherapy. Results: The results proved that the use of intra-arterial neoadjuvant chemotherapy (IACT) has a better degree of tumor regression (p0.05) between the variants of neoadjuvant therapy. Conclusions: In the treatment of patients with malignant tumors of the mediastinum and chest wall, the use of neoadjuvant therapy is mandatory. When a malignant tumor is localized in the anterior mediastinum, anterior and side wall of the chest, in the blood circulation zone of a. thoracica interna, a promising variant of neoadjuvant therapy is intra-arterial regional chemotherapy.
- 28 June 2023
- Published by John Paul II University in Biała Podlaska in Health Problems of Civilization
- Vol. 17 (2) , 114-121
Open AccessEFFICIENCY OF NEOADJUVANT THERAPY OF MALIGNANT TUMORS OF THE MEDIASTINAL AND CHEST WALL
Background: Primary tumors of the mediastinum and chest wall are heterogeneous in morphological structure, united only by anatomical localization. Considering their proximity to the vital structures of the mediastinum, their treatment is a complex task that requires a personalized approach in the selection of neoadjuvant therapy. Material and methods: The results of surgical, combined and complex treatment of 1,375 patients with primary malignant tumors of the mediastinum, and 98 patients with malignant tumors of the chest wall were analyzed. Various treatment methods were used in the neoadjuvant regime: radiotherapy, thermoradiotherapy, chemoradiotherapy and intra-arterial regional chemotherapy. Results: The results proved that the use of intra-arterial neoadjuvant chemotherapy (IACT) has a better degree of tumor regression (p0.05) between the variants of neoadjuvant therapy. Conclusions: In the treatment of patients with malignant tumors of the mediastinum and chest wall, the use of neoadjuvant therapy is mandatory. When a malignant tumor is localized in the anterior mediastinum, anterior and side wall of the chest, in the blood circulation zone of a. thoracica interna, a promising variant of neoadjuvant therapy is intra-arterial regional chemotherapy.
- Open Access
- 26 May 2023
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Experimental Oncology
- Vol. 44 (3) , 178-185
OVERVIEW OF DISCUSSIONS AND DECISION-MAKING ON TOTAL NEOADJUVANT THERAPY OF DISTAL RECTAL CANCER
Advances implemented in the complex treatment of distal rectal cancer led to a decrease in the number of loco-regional recurrences to 5–10%, but high rates of distant metastases remain at up to 30%. They lead to disappointing long-term oncological results, which requires the search for improvement of each of the stages of complex treatment. As a consequence of the questionable effectiveness of adjuvant polychemotherapy for distal rectal cancer, the question of the possibility of transferring drug treatment from an adjuvant to a neoadjuvant regimen is reasonably raised. The presented options for full neoadjuvant therapy have been developed and tested in leading oncology centers and are based on National Comprehensive Cancer Network Version 1.2022 recommendations. It is premature to make categorical conclusions regarding the recommendation of one or another variant of their implementation. Our preliminary clinical results confirmed the need for an additional stage of restaging in the second option, after 16 weeks of polychemotherapy before chemoradiation, in order to exclude the generalization of the disease. Therefore, there is a need for a prospective, controlled intercentre study to answer some unresolved questions.
- 26 May 2023
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Experimental Oncology
- Vol. 44 (3) , 178-185
Open AccessOVERVIEW OF DISCUSSIONS AND DECISION-MAKING ON TOTAL NEOADJUVANT THERAPY OF DISTAL RECTAL CANCER
Advances implemented in the complex treatment of distal rectal cancer led to a decrease in the number of loco-regional recurrences to 5–10%, but high rates of distant metastases remain at up to 30%. They lead to disappointing long-term oncological results, which requires the search for improvement of each of the stages of complex treatment. As a consequence of the questionable effectiveness of adjuvant polychemotherapy for distal rectal cancer, the question of the possibility of transferring drug treatment from an adjuvant to a neoadjuvant regimen is reasonably raised. The presented options for full neoadjuvant therapy have been developed and tested in leading oncology centers and are based on National Comprehensive Cancer Network Version 1.2022 recommendations. It is premature to make categorical conclusions regarding the recommendation of one or another variant of their implementation. Our preliminary clinical results confirmed the need for an additional stage of restaging in the second option, after 16 weeks of polychemotherapy before chemoradiation, in order to exclude the generalization of the disease. Therefore, there is a need for a prospective, controlled intercentre study to answer some unresolved questions.
- Open Access
- 24 October 2022
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 26 (3) , 191-195
A view on the problem of providing oncological aid during the war in Ukraine
Introduction Providing oncological care in conflict conditions is a difficult test for the country’s health care system, especially if aggression is carried out in violation of the main international rules of conduct of war, the treaties of the Geneva Convention, when the aggressor attacks the...
- 24 October 2022
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 26 (3) , 191-195
Open AccessA view on the problem of providing oncological aid during the war in Ukraine
Introduction Providing oncological care in conflict conditions is a difficult test for the country’s health care system, especially if aggression is carried out in violation of the main international rules of conduct of war, the treaties of the Geneva Convention, when the aggressor attacks the...
- Open Access
- 28 November 2021
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 88 (9-10) , 95-98
Primary synovial mediastinal sarcomas
Primary synovial mediastinal sarcomas
- 28 November 2021
- Published by Liga-Inform, Ltd. in Klinicheskaia khirurgiia
- Vol. 88 (9-10) , 95-98
Open AccessPrimary synovial mediastinal sarcomas
Primary synovial mediastinal sarcomas